Trastuzumab and gemcitabine in pretreated HER2 overexpressing metastatic breast cancer patients: Retrospective analysis of our series

Journal of Oncology

Volumn , Issue , 2012, Pages

  Di Lauro, Vincenzo ^a   Torrisi, Elena ^a   Bidoli, Ettore ^a   Quitadamo, Daniela ^a   Cecco, Sara ^a   Veronesi, Andrea ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CHLORPHENIRAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; LAPATINIB; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; GENE OVEREXPRESSION; HUMAN; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; RETROSPECTIVE STUDY; STOMATITIS; VOMITING;

EID: 84859765119     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/198412     Document Type: Article

References (32)

1. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987 235 4785 182 191
2. Paik S., Hazan R., Fisher E. R., Sass R. E., Fisher B., Redmond C., Schlessinger J., Lippman M. E., King C. R., Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer Journal of Clinical Oncology 1990 8 1 103 112 (Pubitemid 20032452)
3. Dawood S., Broglio K., Buzdar A. U., Hortobagyi G. N., Giordano S. H., Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review Journal of Clinical Oncology 2010 28 1 92 98
4. Vogel C. L., Cobleigh M. A., Tripathy D., Gutheil J. C., Harris L. N., Fehrenbacher L., Slamon D. J., Murphy M., Novotny W. F., Burchmore M., Shak S., Stewart S. J., Press M., Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer Journal of Clinical Oncology 2002 20 3 719 726 (Pubitemid 34111379)
5. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C. C., Dantis L., Sklarin N. T., Seidman A. D., Hudis C. A., Moore J., Rosen P. P., Twaddell T., Henderson I. C., Norton L., Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer Journal of Clinical Oncology 1996 14 3 737 744
6. Cobleigh M. A., Vogel C. L., Tripathy D., Robert N. J., Scholl S., Fehrenbacher L., Wolter J. M., Paton V., Shak S., Lieberman G., Slamon D. J., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease Journal of Clinical Oncology 1999 17 9 2639 2648 (Pubitemid 29415219)
7. Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L., Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2 The New England Journal of Medicine 2001 344 11 783 792 (Pubitemid 32222155)
8. Pegram M. D., Konecny G. E., O'Callaghan C., Beryt M., Pietras R., Slamon D. J., Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer Journal of the National Cancer Institute 2004 96 10 739 749 (Pubitemid 38771819)
9. Di Lauro V., Murrone A., Bidoli E., Magri M. D., Crivellari D., Veronesi A., Trastuzumab and vinorelbine as highly effective and safe therapy for HER-2-overexpressing metastatic breast cancer. A single institution experience Tumori 2008 94 4 464 468
10. Burstein H. J., Kuter I., Campos S. M., Gelman R. S., Tribou L., Parker L. M., Manola J., Younger J., Matulonis U., Bunnell C. A., Partridge A. H., Richardson P. G., Clarke K., Shulman L. N., Winer E. P., Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer Journal of Clinical Oncology 2001 19 10 2722 2730 (Pubitemid 32441378)
11. Jahanzeb M., Mortimer J. E., Yunus F., Irwin D. H., Speyer J., Koletsky A. J., Klein P., Sabir T., Kronish L., Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2 + metastatic breast cancer The Oncologist 2002 7 5 410 417 (Pubitemid 35266133)
12. Chan A., A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer Annals of Oncology 2007 18 7 1152 1158 (Pubitemid 47244359)
13. Chan A., Petruzelka L., Untch M., Long term survival of vinorelbine and trastuzumab as first line therapy for HER2-positive metastatic breast cancer patients Journal of Clinical Oncology 2005 23 supplement 16, abstract 587
14. De Wit M., Becker K., Thomssen C., Vinorelbine and trastuzumab as first line therapy in patients with Her2-positive metastatic breast cancer: interim analysis of a prospective open-label, multicentre phase II trial Annals of Oncology 2004 3 supplement 15, abstract 138P
15. Burstein H. J., Harris L. N., Marcom P. K., Lambert-Falls R., Havlin K., Overmoyer B., Friedlander Jr. R. J., Gargiulo J., Strenger R., Vogel C. L., Ryan P. D., Ellis M. J., Nunes R. A., Bunnell C. A., Campos S. M., Hallor M., Gelman R., Winer E. P., Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm Journal of Clinical Oncology 2003 21 15 2889 2895 (Pubitemid 46621838)
16. Papaldo P., Fabi A., Ferretti G., Mottolese M., Cianciulli A. M., Di Cocco B., Pino M. S., Carlini P., Di Cosimo S., Sacchi I., Sperduti I., Nardoni C., Cognetti F., A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease Annals of Oncology 2006 17 4 630 636
17. Bayo-Calero J. l., Mayordomo-Camara J. l., Sanchez-Rovira P., A multicenter study with trastuzumab and vinorelbine as first and second line treatment in patients with HER2 positive metastatic breast cancer Breast Cancer Research and Treatment 2004 88 supplement 1, abstract 5096 207 208
18. Suzuki Y., Tokuda Y., Saito Y., Ohta M., Tajima T., Combination of trastuzumab and vinorelbine in metastatic breast cancer Japanese Journal of Clinical Oncology 2003 33 10 514 517 (Pubitemid 43115244)
19. Garca-Senz J. A., Martn M., Puente J., Lpez-Tarruella S., Casado A., Moreno F., Grande E., Daz-Rubio E., Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer Clinical Breast Cancer 2005 6 4 325 329 (Pubitemid 41715693)
20. Burstein H. J., Keshaviah A., Baron A. D., Hart R. D., Lambert-Falls R., Marcom P. K., Gelman R., Winer E. P., Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study Cancer 2007 110 5 965 972 (Pubitemid 47312860)
21. Andersson M., Lidbrink E., Bjerre K., Wist E., Enevoldsen K., Jensen A. B., Karlsson P., Tange U. B., Srensen P. G., Mller S., Bergh J., Langkjer S. T., Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study Journal of Clinical Oncology 2011 29 3 264 271
22. Bunn P. A., Helfrich B., Soriano A. F., Franklin W. A., Varella-Garcia M., Hirsch F. R., Baron A., Zeng C., Chan D. C., Expression of Her-2/ neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents Clinical Cancer Research 2001 7 10 3239 3250 (Pubitemid 32963849)
23. O'Shaughnessy J. A., Vukelja S., Marsland T., Kimmel G., Ratnam S., Pippen J. E., Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer Clinical Breast Cancer 2004 5 2 142 147 (Pubitemid 39029207)
24. Miller A. B., Hoogstraten B., Staquet M., Winkler A., Reporting results of cancer treatment Cancer 1981 47 1 207 214 (Pubitemid 11167383)
25. NCI-CTCAE grade v3.0: National Cancer Institute Common Terminology Criteria for Adverse Events
26. Jahanzeb M., Trastuzumab-based combinations in metastatic breast cancer: how to make a choice Clinical Breast Cancer 2003 4 1 28 38 (Pubitemid 36621621)
27. Yardley D. A., Burris H. A., Hanson S., Greco F. A., Spigel D. R., Barton J., Hainsworth J. D., Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer Clinical Breast Cancer 2009 9 3 178 183
28. Von Minckwitz G., du Bois A., Schmidt M., Maass N., Cufer T., De Jongh F. E., Maartense E., Zielinski C., Kaufmann M., Bauer W., Baumann K. H., Clemens M. R., Duerr R., Uleer C., Andersson M., Stein R. C., Nekljudova V., Loibl S., Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 0305 study Journal of Clinical Oncology 2009 27 12 1999 2006
29. Geyer C. E., Forster J., Lindquist D., Chan S., Romieu C. G., Pienkowski T., Jagiello-Gruszfeld A., Crown J., Chan A., Kaufman B., Skarlos D., Campone M., Davidson N., Berger M., Oliva C., Rubin S. D., Stein S., Cameron D., Lapatinib plus capecitabine for HER2-positive advanced breast cancer The New England Journal of Medicine 2006 355 2733 2743 (Pubitemid 46021510)
30. Burris H. A. III, Rugo H. S., Vukelja S. J., Vogel C. L., Borson R. A., Limentani S., Tan-Chiu E., Krop I. E., Michaelson R. A., Girish S., Amler L., Zheng M., Chu Y.-W., Klencke B., O'Shaughnessy J. A., Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy Journal of Clinical Oncology 2011 29 4 398 405
31. Baselga J., Gelmon K. A., Verma S., Wardley A., Conte P., Miles D., Bianchi G., Cortes J., McNally V. A., Ross G. A., Fumoleau P., Gianni L., Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy Journal of Clinical Oncology 2010 28 7 1138 1144
32. Burstein H. J., Sun Y., Dirix L. Y., Jiang Z., Paridaens R., Tan A. R., Awada A., Ranade A., Jiao S., Schwartz G., Abbas R., Powell C., Turnbull K., Vermette J., Zacharchuk C., Badwe R., Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer Journal of Clinical Oncology 2010 28 8 1301 1307